Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

375
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
375
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

866
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
866
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

866
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
866
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  2. 研究分野
  3. 生物医学と臨床科学
  4. 心血管医学と血液学
  5. 心臓病 (心血管疾患を含む)
  6. ハンティントン病:治療における新興分野 (レビュー)
  1. ホーム
  2. 研究分野
  3. 生物医学と臨床科学
  4. 心血管医学と血液学
  5. 心臓病 (心血管疾患を含む)
  6. ハンティントン病:治療における新興分野 (レビュー)

関連する実験動画

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

9.7K

ハンティントン病:治療における新興分野 (レビュー)

Aisha Tahir1, Sania Jamal2, Usman Ali Shams3

  • 1Department of Biochemistry, University of Health Sciences, Khayaban-e- Jamia Punjab, 54600, Lahore, Punjab, Pakistan. dr.aisha@uhs.edu.pk.

Neurogenetics
|September 6, 2025

PubMed で要約を見る

まとめ
この要約は機械生成です。

ハンチントン病 (HD) は遺伝的神経変性疾患である. 新しい治療法では 変異したハンティングチンのタンパク質を標的として 病気を修正し 治療への希望を与えています

キーワード:
ASO についてCAG 繰り返すCRISPRについて遺伝子療法

さらに関連する動画

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

10.7K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.0K

関連する実験動画

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

9.7K
Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

10.7K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.0K

科学分野:

  • 神経科学
  • 遺伝学
  • 分子生物学

背景:

  • ハンチントン病 (HD) は進行性神経変性疾患である.
  • 運動,認知,精神的な症状が特徴です.
  • ハンチングチンの遺伝子の CAG 繰り返し拡張により発生し 毒性のあるハンチングチンのタンパク質が 結合します

研究 の 目的:

  • ハンチントン病の病原性を見直すため
  • HDの現在と新興の治療戦略について議論する.
  • 病気を修正する介入への移行を強調する.

主な方法:

  • HD病原性における遺伝的,分子的,環境的要因の文献レビュー
  • 現在の管理方法の分析
  • RNA干渉,反意味オリゴヌクレオチド (ASO),ペプチド阻害剤,CRISPR/Cas9遺伝子編集を含む新しい治療戦略の探索.

主要な成果:

  • HD に寄与する 遺伝的,分子的,環境的要因を特定した.
  • 様々な管理戦略を詳細に述べています.
  • ASOや遺伝子編集のような 有望な治療法を紹介しました
HTT遺伝子
ハンティントン病
RNAi について

結論:

  • 新しい治療法の進歩は HDの進行を修正する動きを示しています
  • ハンティントン病の治療には 進歩が進んでいるにもかかわらず 更に研究が必要です
  • 効果的な治療法の開発には 継続的な臨床研究と翻訳研究が不可欠です